Tech Company Financing Transactions

Revance Therapeutics Funding Round

Medicis Pharmaceutical, EW Healthcare Partners and Palo Alto Investors participated in a $43.2 million Series C funding round for Revance Therapeutics. The financing round was announced on 12/12/2007.

Transaction Overview

Company Name
Revance Therapeutics
Announced On
12/12/2007
Transaction Type
Venture Equity
Amount
$43,200,000
Round
Series C
Investors

Medicis Pharmaceutical (Lead Investor) (Jonah Shacknai)

EW Healthcare Partners (Phyllis Gardner)

Palo Alto Investors

Shepherd Ventures

Technology Partners (James Glasheen)

Vivo Capital (Frank Kung)

Proceeds Purpose
Additionally, Medicis has committed to make further equity investments in Revance of up to $5 million under certain terms and prior to the exercise of the option to acquire Revance or to license exclusively Revance's topical botulinum toxin type A product in North America. Separately, Medicis and Revance have also agreed to engage in exclusive negotiations regarding a development program relating to the application of Revance's proprietary drug delivery technology to other agents and selected dermatological targets.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1222 Demonbreun St. 2000
Nashville, TN 37203
USA
Phone
(510) 742-3400
Website
www.revance.com
Email Address
[email protected]
Overview
Revance (NASDAQ: RVNC) is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance's platform technologies to enhance patient tolerability of botulinum toxin.
Profile
Revance Therapeutics LinkedIn Company Profile
Social Media
Revance Therapeutics Company Twitter Account
Company News
Revance Therapeutics News
Facebook
Revance Therapeutics on Facebook
YouTube
Revance Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mark Foley
  Mark Foley LinkedIn Profile  Mark Foley Twitter Account  Mark Foley News  Mark Foley on Facebook
Chief Financial Officer
Tobin Schilke
  Tobin Schilke LinkedIn Profile  Tobin Schilke Twitter Account  Tobin Schilke News  Tobin Schilke on Facebook
Chief Operating Officer
Abhay Joshi
  Abhay Joshi LinkedIn Profile  Abhay Joshi Twitter Account  Abhay Joshi News  Abhay Joshi on Facebook
VP - Bus. Development
Dustin Sjuts
  Dustin Sjuts LinkedIn Profile  Dustin Sjuts Twitter Account  Dustin Sjuts News  Dustin Sjuts on Facebook
VP - Human Resources
Justin Ford
  Justin Ford LinkedIn Profile  Justin Ford Twitter Account  Justin Ford News  Justin Ford on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/12/2007: Cleversafe venture capital transaction
Next: 12/12/2007: Energy and Power Solutions venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.